本文已被：浏览 1772次 下载 2次
中文摘要: 目的 观察瑞舒伐他汀联合氯吡格雷对冠心病心绞痛患者疗效及组织型纤溶酶原激活物抑制剂-1（tPAI-1）、单核细胞趋化因子-1（MCP-1）及可溶性E选择素（sE-selectin）的影响。方法 选取我院收治的冠心病心绞痛患者112例作为研究对象，按照随机数字表法分为观察组和对照组各56例，2组均给予常规治疗，在此基础上对照组给予氯吡格雷治疗，观察组在对照组基础上联合瑞舒伐他汀治疗。观察2组临床疗效、甘油三酯（TG）、高密度脂蛋白（HDL-C）、总胆固醇（TC）、低密度脂蛋白（LDL-C）、 tPAI-1、MCP-1及sE-selectin水平。结果 观察组总有效率91.07%显著高于对照组75.00%（P＜0.05）；治疗后2组TG、TC、LDL-C水平显著低于治疗前（P＜0.05），且观察组显著低于对照组（P＜0.05），2组HDL-C水平显著高于治疗前（P＜0.05），且观察组显著高于对照组（P＜0.05）；治疗后2组tPAI-1、MCP-1、sE-selectin水平显著低于治疗前（P＜0.05），且观察组显著低于对照组（P＜0.05）。结论 瑞舒伐他汀联合氯吡格雷能够有效降低冠心病心绞痛患者血脂、tPAI-1、MCP-1及sE-selectin水平，提高临床疗效。
Abstract:OBJECTIVE To observe the influence of rosuvastatin combined with clopidogrel on Curative effect and tissue type plasminogen activator inhibitor -1 (tPAI-1), monocyte chemotactic factor -1 (MCP-1) and soluble E selectin (sE-selectin) of patients with coronary heart disease complicated with angina pectoris. METHODS 112 cases of patients with coronary heart disease complicated with angina pectoris treated in our hospital were selected as the study object, and were divided into the observation group and the control group according to random number table method, 56 cases in each group. All the two groups were given conventional treatment, and the control group were given clopidogrel therapy on the basis of that, and the observation group were combined with rosuvastatin therapy on the basis of the control group. The control group were given routine nursing intervention, and the study group were given full featured rehabilitation nursing of traditional Chinese Medicine intervention on the basis of the control group. Clinical effect, triglyceride (TG), high-density lipoprotein (HDL-C), total cholesterol (TC), low-density lipoprotein (LDL-C), tPAI-1, MCP-1 and sE-selectin levels were observed in the two groups.
RESULTS total effective rate of the observation group was 91.07%, significantly
higher than that of 75.00% of the control group (P＜ 0.05). After treatment, TG, TC and LDL-C levels were significantly lower than those before treatment in the two groups(P＜0.05), which in the observation group were significantly lower than those in the control group (P＜0.05). HDL-C level was significantly higher than that before treatment in the two groups (P＜0.05), and that in the observation group was significantly higher than that in the control group (P＜0.05). After treatment, tPAI-1, MCP-1 and sE-selectin levels in the two groups were significantly lower than those before treatment (P＜0.05), which of the observation group were significantly lower than those in the control group (P＜0.05). CONCLUSION Rosuvastatin combined with clopidogrel can effectively reduce serum lipids, tPAI-1, MCP-1 and sE-selectin levels of patients with coronary heart disease complicated with angina pectoris, and improve clinical effect.
文章编号：3201712028 中图分类号：R972 文献标志码：
基金项目:
引用文本：